• Trials of Gilead's remdesivir in Covid-19 not diverse enough, experts write

    1 month ago - By MedCity News

    In a commentary, physicians and pharmacists wrote that percentages of Black, Latino and Native American patients in two Phase III studies of the drug that the company is using for FDA approval were disproportionate to Covid-19's incidence in those communities.
    Read more ...